NO975581L - Fremgangsmåte for å redusere bentap - Google Patents

Fremgangsmåte for å redusere bentap

Info

Publication number
NO975581L
NO975581L NO975581A NO975581A NO975581L NO 975581 L NO975581 L NO 975581L NO 975581 A NO975581 A NO 975581A NO 975581 A NO975581 A NO 975581A NO 975581 L NO975581 L NO 975581L
Authority
NO
Norway
Prior art keywords
formula
bone loss
pyrrolidinyl
alkyl
compound
Prior art date
Application number
NO975581A
Other languages
English (en)
Other versions
NO975581D0 (no
Inventor
George Joseph Cullinan
Steven Anthony Fontana
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO975581D0 publication Critical patent/NO975581D0/no
Publication of NO975581L publication Critical patent/NO975581L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Glass Compositions (AREA)

Abstract

Foreliggende oppfinnelse skaffer tilveie en fremgangsmåte for å redusere bentapeffekt av en forbindelse med formel II eller et farmasøytisk akseptabelt salt derav, der nevnte formel II blir administrert til et pattedyr som har behov for behandling, og omfatter samtidig eller sekvensiell administrering til nevnte pattedyr av en effektiv mengde av en forbindelse med formel I, der hver R1 er uavhengig av hverandre -H, -OH, -0(CCalkyl), -OCOCH, -OCO(C,-Calkyl) eller -OS0(C-Calkyl); og R2 er 1-piperidinyl, 1-pyrrolidinyl, metyl-1-pyrrolidinyI, dimetyl-l-pyrrolidinyl, 4-morfolino, dimetylamino, dietylamino eller 1-heksametylenimino, eller et farmasøytisk akseptabelt salt derav. Det blir også beskrevet en fremgangsmåte for å begrense bentap indusert ved administrering av en formel II forbindelse og omfatter samtidig eller sekvensiell administrering av et benanabolsk middel. Det blir også beskrevet farmasøytiske sammensetninger.
NO975581A 1995-06-06 1997-12-03 Fremgangsmåte for å redusere bentap NO975581L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/467,475 US5599822A (en) 1995-06-06 1995-06-06 Methods for minimizing bone loss
PCT/US1996/008875 WO1996039138A1 (en) 1995-06-06 1996-06-05 Methods for minimizing bone loss

Publications (2)

Publication Number Publication Date
NO975581D0 NO975581D0 (no) 1997-12-03
NO975581L true NO975581L (no) 1997-12-03

Family

ID=23855853

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975581A NO975581L (no) 1995-06-06 1997-12-03 Fremgangsmåte for å redusere bentap

Country Status (22)

Country Link
US (1) US5599822A (no)
EP (1) EP0747054B1 (no)
JP (1) JPH11507051A (no)
KR (1) KR19990022498A (no)
CN (1) CN1192145A (no)
AU (1) AU696209B2 (no)
BR (1) BR9608389A (no)
CA (1) CA2223055A1 (no)
CO (1) CO4700446A1 (no)
CZ (1) CZ382997A3 (no)
DE (1) DE69623074T2 (no)
EA (1) EA000763B1 (no)
ES (1) ES2181849T3 (no)
HU (1) HUP9900849A3 (no)
IL (1) IL118590A (no)
NO (1) NO975581L (no)
PL (1) PL323935A1 (no)
TR (1) TR199701507T1 (no)
TW (1) TW372969B (no)
WO (1) WO1996039138A1 (no)
YU (1) YU34396A (no)
ZA (1) ZA964778B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
WO2001035946A2 (en) * 1999-11-15 2001-05-25 New Millennium Pharmaceutical Research, Inc. Intranasal administration of raloxifene and tamoxifen
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1180364A1 (en) * 2000-08-15 2002-02-20 Octagene GmbH Steroid hormones as transfer agents
EP1530470B9 (en) 2002-07-22 2010-04-07 Eli Lilly And Company Selective estrogen receptor modulators containing a phenylsulfonyl group
CN101151048A (zh) 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
JP5007427B2 (ja) * 2004-05-13 2012-08-22 アルザ コーポレイション 副甲状腺ホルモン剤の経皮送達のための装置および方法
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
EP1931374A2 (en) * 2005-10-06 2008-06-18 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US11253498B2 (en) * 2017-06-01 2022-02-22 Nexyon Biotech Co., Ltd. Pharmaceutical composition for treatment of bone-related disease
CN108785264A (zh) * 2018-07-03 2018-11-13 威海贯标信息科技有限公司 一种达那唑片剂组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) * 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
CO4700446A1 (es) 1998-12-29
ES2181849T3 (es) 2003-03-01
EP0747054A3 (en) 1997-03-05
YU34396A (sh) 1999-07-28
NO975581D0 (no) 1997-12-03
CA2223055A1 (en) 1996-12-12
JPH11507051A (ja) 1999-06-22
TR199701507T1 (xx) 1998-02-21
DE69623074D1 (de) 2002-09-26
KR19990022498A (ko) 1999-03-25
TW372969B (en) 1999-11-01
CN1192145A (zh) 1998-09-02
ZA964778B (en) 1997-12-08
HUP9900849A3 (en) 1999-11-29
WO1996039138A1 (en) 1996-12-12
EA000763B1 (ru) 2000-04-24
CZ382997A3 (cs) 1998-09-16
IL118590A0 (en) 1996-10-16
US5599822A (en) 1997-02-04
HUP9900849A2 (hu) 1999-09-28
DE69623074T2 (de) 2003-05-08
IL118590A (en) 1999-10-28
EP0747054B1 (en) 2002-08-21
PL323935A1 (en) 1998-04-27
EP0747054A2 (en) 1996-12-11
BR9608389A (pt) 1999-05-04
AU696209B2 (en) 1998-09-03
EA199800013A1 (ru) 1998-06-25
AU6043096A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
NO975581L (no) Fremgangsmåte for å redusere bentap
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
RU94043811A (ru) Применение 2-фенил-3-ароилбензтиофенов для лечения менструальных симптомов, фармацевтические композиции
RU2004116472A (ru) Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3
PT958296E (pt) Compostos heterociclicos processo para a sua preparacao composicoes farmaceuticas contendo-os e sua utilizacao no tratamento da diabetes e doencas relacionadas
NO20063382L (no) Nye kinolinderivater
KR960701033A (ko) 효능있는 칼슘 길항 및 산화방지 활성을 모두 갖는 화합물, 및 세포보호제로서 그것의 사용방법(compounds having both potent calcium antagonist and antioxidant activity and use there of as cytoprotective agents)
KR950700265A (ko) 고지혈증 치료에 유용한 벤조티아제핀 화합물(hypolipidaemic ben zothiazepine compounds)
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
AR003930A1 (es) Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados
RU94045149A (ru) Средство ингибирования легочных гипертонических заболеваний
BR9807079A (pt) Composto de derivado de 16-hidróxi-11- (fenil substituìdo) - estra-4,9-dieno, uso de um composto, formulação farmacêutica, e processo para a preparação de um composto.
ATE240948T1 (de) Naphthyl- und dihydronaphthylverbindungen als arzneimittel
KR940703655A (ko) 약제학적 조성물과 그 제조방법
ATE269865T1 (de) Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
DE69532079D1 (de) Benzofuranverbindungen, präparate und verfahren
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
MY106401A (en) N-imidazolyl-and-n-imidazolymethyl-derivatives of substituted bicyclic compounds.
RU94045272A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения овариального дисгенеза, задержки полового созревания или сексуального инфантелизма
DK0733035T3 (da) Tricykliske derivater og farmaceutiske præparater, der indeholder dem
KR940009179A (ko) 벤조푸란 유도체, 그의 제조 방법, 그를 함유한 제약조성물 및 그의 의약으로서의 용도
NO975560L (no) Fremgangsmåte for å redusere bentap
NO971229D0 (no) Fremgangsmåte for minimalisering av den uterotrofiske effekt av tamoxifen og tamoxifenanaloger

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application